Novartis Reduces Outsourcing Through Parexel; CRO To Lay Off 400-500
Executive Summary
Novartis' cancellation of several outsourcing contracts with Parexel could result in a reduction of the contract research organization's workforce by 400-500 positions, Parexel said.
You may also be interested in...
Covance Seeks Outside Investor For Expansion Of Biomanufacturing Business
Covance is seeking a third-party investment of several hundred million dollars to expand its commercial biomanufacturing business to meet growing demand.
Covance Seeks Outside Investor For Expansion Of Biomanufacturing Business
Covance is seeking a third-party investment of several hundred million dollars to expand its commercial biomanufacturing business to meet growing demand.
The XenoMouse That Roared: Cell Genesys' Share Of Abgenix Worth $781 Mil.
Cell Genesys' 12% share of Abgenix at the end of February is worth more than twice the value of Genzyme's attempted acquisition of Cell Genesys in October.